VIPR1 polyclonal Antibody | BS60880

VIPR1 polyclonal Antibody | BS60880 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: The vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating polypeptide (PACAP) belong to a superfamily of peptide hormones that include glucagon, secretin and growth hormone releasing hormone (1,2) . The effects of VIP and PACAP are mediated by three G-protein coupled receptors, VPAC1, VPAC2 and the PACAP receptor (also designated PAC1-R) (1,2) . The VPAC receptors have equal affinities for VIP and PACAP, which stimulate the activation of adenylyl cyclase (1,3) . Both VPAC1 and VPAC2 are abundantly expressed in brain and T cells, where they modulate neuronal differentiation and T cell activation, respectively (1,4-6) . The PACAP receptor is a seven transmembrane protein that produces at least eight isoforms by alternative splicing (2) . Each isoform is associated with a specific signaling pathway and a specific expression pattern (2) . The PACAP receptor, which is thought to play an integral role in brain development, preferentially binds PACAP in order to stimulate a cAMP-protein kinase A signaling pathway (2,7) .

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: VIPR1 polyclonal Antibody detects endogenous levels of VIPR1 protein.

Molecular Weight: ~ 52 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Vasoactive intestinal polypeptide receptor 1; VIP-R-1; Pituitary adenylate cyclase-activating polypeptide type II receptor; PACAP type II receptor; PACAP-R-2; PACAP-R2; VPAC1; VIPR1

Immunogen: A synthetic peptide corresponding to residues in Human VIPR1.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: